Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-Driven Treatment Strategy Versus Pola-R-CHP in Previously Untreated Large B-Cell Lymphoma
NCT07594899Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zanubrutinib, lenalidomide, decitabine and glofitamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Progression-free survival up to 24 months. Planned start May 2026; status: not yet recruiting.
02
Drugs
zanubrutiniblenalidomidedecitabineglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07594899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594899.